AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and breakout targets.

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

Biopharmaceutical company AbbVie has reached an agreement with the Trump administration to invest $100 billion in its U.S.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.